
****

**TABLE OF CONTENTS**

[1. REPORT OVERVIEW 14](#_Toc72064709)

[1.1 Statement of the Report 14](#_Toc72064710)

[1.2 Executive Summary 16](#_Toc72064711)

[1.3 Introduction 17](#_Toc72064712)

[2. CHIMERIC ANTIGEN RECEPTOR-T (CAR-T) CELL THERAPY: A BRIEF OVERVIEW 18](#_Toc72064713)

[2.1 CAR-T Cell 19](#_Toc72064714)

[2.2 Evolution of CAR-T Cell Development 20](#_Toc72064715)

[2.2.1 The CAR-T Cell Family 20](#_Toc72064716)

[2.2.1.1 First Generation CARs 21](#_Toc72064717)

[2.2.1.2 Second Generation CARs 22](#_Toc72064718)

[2.2.1.3 Third Generation CARs 22](#_Toc72064719)

[2.2.1.4 Fourth Generation CARs 23](#_Toc72064720)

[2.3 Antigens Present on Hematological Cancer Cells 23](#_Toc72064721)

[2.4 Tools for Inserting Receptor Genes into T Cells 24](#_Toc72064722)

[2.5 Transforming T Cells into CAR-T Cells 24](#_Toc72064723)

[2.6 The Four CAR-T Therapies Crossing the Finishing Line 25](#_Toc72064724)

[2.7 Toxicities Associated with CAR-T Treatment 27](#_Toc72064725)

[2.8 The Future of CAR-T Cell Therapy 28](#_Toc72064726)

[2.8.1 Transition from Liquid Cancers to Solid Tumors 29](#_Toc72064727)

[2.8.2 Reduction in the Length of Hospital Stay 30](#_Toc72064728)

[2.8.3 Discovery of New Target Antigens 30](#_Toc72064729)

[2.8.4 Shifting from Autologous to Allogeneic CAR-T Therapy 31](#_Toc72064730)

[2.8.5 CAR-T for the Masses 33](#_Toc72064731)

[2.9 Advantages of CAR-T Therapy 33](#_Toc72064732)

[2.10 Disadvantages of CAR-T Therapy 34](#_Toc72064733)

[3. A BRIEF HISTORY OF CAR-T CELL THERAPY 35](#_Toc72064734)

[3.1 Current Status of CAR-T Therapy Products 36](#_Toc72064735)

[3.2 Prospective CAR-T Product Candidates 36](#_Toc72064736)

[3.3 Transformative Potential of CAR-T Therapy 37](#_Toc72064737)

[3.4 Small Patient Population & Huge Clinical Trial Landscape 38](#_Toc72064738)

[4. MANUFACTURE OF CAR-T CELLS 39](#_Toc72064739)

[4.1 Automation in CAR-T Manufacturing 41](#_Toc72064740)

[4.2 Operating Expenses in Autologous CAR-T Manufacturing 42](#_Toc72064741)

[4.3 Operating Expenses in Allogeneic CAR-T Manufacturing 43](#_Toc72064742)

[5. CAR-T TARGET ANTIGENS: A BRIEF OVERVIEW 44](#_Toc72064743)

[5.1 CAR-T Target Antigens on Hematological Cancers 44](#_Toc72064744)

[5.2 CAR-T Target Antigens on Solid Tumors 45](#_Toc72064745)

[5.3 Common Antigens Targeted by CAR-T Cells 46](#_Toc72064746)

[5.3.1 Cluster of Differentiation 19 (CD19) 47](#_Toc72064747)

[5.3.2 Mesothelin 47](#_Toc72064748)

[5.3.3 B-Cell Maturation Agent (BCMA) 47](#_Toc72064749)

[5.3.4 GD2 48](#_Toc72064750)

[5.3.5 Glypican-3 (GPC3) 48](#_Toc72064751)

[5.3.6 Cluster Differentiation-22 (CD22) 48](#_Toc72064752)

[6. CAR-T PATENT LANDSCAPE 49](#_Toc72064753)

[6.1 Geographical Origin of CAR-T Patent Applications 51](#_Toc72064754)

[6.2 Top Ten CAR-T Patent Jurisdictions 51](#_Toc72064755)

[6.3 Affiliations of CAR-T Cell Patent Applicants 52](#_Toc72064756)

[6.3.1 Top 20 Companies in CAR-T Patent Landscape 53](#_Toc72064757)

[6.3.2 TOP 20 Research Centers in CAR-T Patent Landscape 54](#_Toc72064758)

[6.3.3 Top 20 CAR-T Cell Inventors 55](#_Toc72064759)

[6.3.4 Top Five CAR-T Patents with Most Family Members 56](#_Toc72064760)

[6.3.5 Top Five CAR-T Patents with Most Inventors in Co-Authorship 57](#_Toc72064761)

[6.3.6 Top Five Patents with Most Co-Applicants 58](#_Toc72064762)

[6.3.7 Top Five CAR-T Patents with Most Citations Received 58](#_Toc72064763)

[7. GLOBAL CAR-T CLINICAL TRIALS: AN OVERVIEW 59](#_Toc72064764)

[7.1 CAR-T Targeted Biomarkers in Clinical Trials 60](#_Toc72064765)

[7.1.1 CAR-T Targeted Biomarkers in U.S. Clinical Trials 61](#_Toc72064766)

[7.1.2 CAR-T Targeted Biomarkers in Chinese Clinical Trials 61](#_Toc72064767)

[7.1.3 CAR-T Targeted Biomarkers in other Countries 62](#_Toc72064768)

[7.2 CAR-T Targeted Indications in the U.S. Clinical Trials 63](#_Toc72064769)

[7.3 Indications Addressed by CAR-T Clinical Trials in China 64](#_Toc72064770)

[7.4 Percent Share of Indications Addressed by the Ongoing CAR-T Clinical Trials 65](#_Toc72064771)

[7.5 Phase of CAR-T Clinical Trials 66](#_Toc72064772)

[7.6 CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S. 67](#_Toc72064773)

[7.7 CAR-T Clinical Trial Sponsor Companies and Institutions in China 69](#_Toc72064774)

[7.8 CAR-T Clinical Trial Sponsor Companies and Institutions in other Countries 72](#_Toc72064775)

[7.9 Ongoing Clinical Trials with Improved CAR-T Constructs 74](#_Toc72064776)

[7.9.1 CAR-T with PD1Fc 74](#_Toc72064777)

[7.9.2 CAR-T with Truncated EGFR (EGFRt) 74](#_Toc72064778)

[7.9.3 CAR-T with IL7 and CCL19 74](#_Toc72064779)

[7.9.4 CAR-T with PD1/CD28 Switch-Receptor 75](#_Toc72064780)

[7.9.5 CAR-T with PD1 shRNA-expressing cassette 75](#_Toc72064781)

[7.9.6 CAR-T with CTLA-4/PD-1 Antibody 75](#_Toc72064782)

[7.9.7 CAR-T with PD-1 Antibodies 75](#_Toc72064783)

[7.10 Geographic Distribution of CAR-T Clinical Trials 81](#_Toc72064784)

[7.11 Distribution of CAR-T Clinical Trials by Type of CAR Generations 81](#_Toc72064785)

[7.12 Distribution of CAR-T Clinical Trials by Type of ScFv Used 82](#_Toc72064786)

[7.13 Distribution of CAR-T Clinical Trials by Type of Vectors Used 83](#_Toc72064787)

[8. PUBLISHED SCIENTIFIC PAPERS & NIH GRANTS 85](#_Toc72064788)

[8.1 Number of Published Papers 85](#_Toc72064789)

[8.2 NIH Funding for CAR-T Research 86](#_Toc72064790)

[9. DEAL-MAKING WITHIN THE CAR-T THERAPY SECTOR 88](#_Toc72064791)

[9.1 Most Recent CAR-T Deals 88](#_Toc72064792)

[9.1.1 Gilead Sciences/Tango Therapeutics 88](#_Toc72064793)

[9.1.2 Kite/Teneobio 88](#_Toc72064794)

[9.1.3 Fate/Janssen 89](#_Toc72064795)

[9.1.4 Juno/Oxford Biomedica 89](#_Toc72064796)

[9.1.5 Allogene/MaxCyte 89](#_Toc72064797)

[9.1.6 Applied DNA Sciences, Inc. 89](#_Toc72064798)

[9.1.7 Cellectis/Servier 90](#_Toc72064799)

[9.1.8 Cell Therapies, Pvt. Ltd 90](#_Toc72064800)

[9.1.9 Astellas/Adaptimmune 90](#_Toc72064801)

[9.1.10 Astellas/Xyphos 90](#_Toc72064802)

[9.1.11 Carisma Therapeutics, Inc./NYU Langone Health 91](#_Toc72064803)

[10. MARKETED CAR-T PRODUCTS 107](#_Toc72064804)

[10.1 Kymriah (Tisagenlecleucel) 107](#_Toc72064805)

[10.1.1 Mechanism of Action 108](#_Toc72064806)

[10.1.2 Dosing 108](#_Toc72064807)

[10.1.3 Safety and Efficacy of Kymriah 108](#_Toc72064808)

[10.1.4 Kymriah’s Cost 109](#_Toc72064809)

[10.1.5 Current Sales of Kymriah 109](#_Toc72064810)

[10.2 Yescarta (Axicabtagene ciloleucel) 110](#_Toc72064811)

[10.2.1 Mechanism of Action 111](#_Toc72064812)

[10.2.3 Dosing 111](#_Toc72064813)

[10.2.4 Safety and Efficacy of Yescarta 111](#_Toc72064814)

[10.2.5 Manufacturing Network 111](#_Toc72064815)

[10.2.6 Current sales of Yescarta 112](#_Toc72064816)

[10.2.7 Sales of Kymriah and Yescarta: A Comparison 112](#_Toc72064817)

[10.3 Tecartus (Brexucabtagene autoleucel) 114](#_Toc72064818)

[10.3.1 Mechanism of Action 114](#_Toc72064819)

[10.3.2 Dosing 114](#_Toc72064820)

[10.3.3 Safety and Efficacy of Tecartus 115](#_Toc72064821)

[10.4 Breyanzi (Lisocabtagene maraleucel) 115](#_Toc72064822)

[10.4.1 Mechanism of Action 115](#_Toc72064823)

[10.4.2 Dosing 116](#_Toc72064824)

[10.4.3 Safety and Efficacy of Breyanzi 116](#_Toc72064825)

[10.4.4 Efficacy, Safety and Composition of Approved CAR-T Products 116](#_Toc72064826)

[10.5 Other Promising CAR-T Product Candidates 117](#_Toc72064827)

[10.5.1 0Idecabtagene Vicleucel (Ide-cel, bb2121) 118](#_Toc72064828)

[10.5.2 ALLO-501 118](#_Toc72064829)

[10.5.3 CTX110 119](#_Toc72064830)

[10.5.4 UCART19 119](#_Toc72064831)

[10.5.5 AUTO1 119](#_Toc72064832)

[10.5.6 JCARH125 119](#_Toc72064833)

[10.5.7 LCAR-B38M 120](#_Toc72064834)

[10.5.8 PBCAR20A 120](#_Toc72064835)

[10.5.9 UCART123 120](#_Toc72064836)

[10.5.10 PRGN-3006 120](#_Toc72064837)

[10.5.11 UCART22 121](#_Toc72064838)

[10.5.12 UCARTCS1 121](#_Toc72064839)

[11. REIMBURSEMENT FOR CAR-T THERAPIES 122](#_Toc72064840)

[11.1 Hospital Reimbursement in the U.S. for CAR-T Therapy 122](#_Toc72064841)

[11.2 Outcomes-Based Reimbursement for CAR-T Therapies in EU5 Countries 123](#_Toc72064842)

[11.2.1 France 123](#_Toc72064843)

[11.2.2 Germany 124](#_Toc72064844)

[11.2.3 Italy 124](#_Toc72064845)

[11.2.4 Spain 125](#_Toc72064846)

[11.2.5 U.K. 125](#_Toc72064847)

[12. BLOOD CANCERS: AN OVERVIEW 126](#_Toc72064848)

[12.1 Lymphoma 126](#_Toc72064849)

[12.1.1 Hodgkin Lymphoma (HL) 127](#_Toc72064850)

[12.1.2 Non-Hodgkin Lymphoma (NHL) 128](#_Toc72064851)

[12.1.2.1 Diffuse Large B Cell Lymphoma (DLBCL) 129](#_Toc72064852)

[12.1.2.2 Follicular Lymphoma (FL) 130](#_Toc72064853)

[12.2 Leukemia 131](#_Toc72064854)

[12.2.1 Types of Leukemia 132](#_Toc72064855)

[12.2.1.1 Acute Myeloid Leukemia (AML) 132](#_Toc72064856)

[12.2.1.2 Acute Lymphoblastic Leukemia (ALL) 133](#_Toc72064857)

[12.2.1.3 Chronic Myeloid Leukemia (CML) 134](#_Toc72064858)

[12.2.1.4 Chronic Lymphocytic Leukemia (CLL) 135](#_Toc72064859)

[12.3 Multiple Myeloma (MM) 136](#_Toc72064860)

[12.4 Treatment Options for Blood Cancers 137](#_Toc72064861)

[12.4.1 Chemotherapy 138](#_Toc72064862)

[12.4.2 Radiation Therapy 139](#_Toc72064863)

[12.4.3 Targeted Therapy 140](#_Toc72064864)

[12.4.4 Stem Cell Transplantation 141](#_Toc72064865)

[12.4.5 Immunotherapy 141](#_Toc72064866)

[12.4.5.1 Monoclonal Antibodies (mAbs) 141](#_Toc72064867)

[12.4.5.2 Immune Check-point Inhibitors 142](#_Toc72064868)

[12.4.5.3 Adoptive Cell Transfer Therapy/T-Cell Transfer Therapy 143](#_Toc72064869)

[12.5 The Staggering Cost of Cancer Therapy 143](#_Toc72064870)

[13. MARKET ANALYSIS 145](#_Toc72064871)

[13.1 Global Market for CAR-T Cell Therapy by Product 145](#_Toc72064872)

[13.2 Global CAR-T Market by Geography 148](#_Toc72064873)

[13.3 Global Market for CAR-T Therapy by Indication 150](#_Toc72064874)

[13.4 Companies at the Forefront of CAR-T Market 152](#_Toc72064875)

[13.5 Barriers and Strategies for Success in CAR-T 2.0 Market Place 152](#_Toc72064876)

[13.5.1 Barriers to CAR-T 2.0 Commercial Success 153](#_Toc72064877)

[13.5.1.1 Capacity Constraints 153](#_Toc72064878)

[13.5.1.2 Competition Among Manufacturers 153](#_Toc72064879)

[13.5.1.3 Competition from Other Treatments 153](#_Toc72064880)

[13.5.2 Market Development Strategies for CAR-T 2.0 154](#_Toc72064881)

[13.5.2.1 Effective Physician Education 154](#_Toc72064882)

[13.5.2.2 Logistical Excellence 154](#_Toc72064883)

[13.5.2.3 Evidence Generation 154](#_Toc72064884)

[14. COMPANY PROFILES 155](#_Toc72064885)

[14.1 Aleta BioTherapeutics 155](#_Toc72064886)

[14.1.1 Atela’s Pipeline 155](#_Toc72064887)

[14.2 Allogene Therapeutics 156](#_Toc72064888)

[14.2.1 AlloCAR-T Therapy 156](#_Toc72064889)

[14.3 Anixa Biosciences, Inc. 157](#_Toc72064890)

[14.4 Atara Biotherapeutics 158](#_Toc72064891)

[14.4.1 Technology 158](#_Toc72064892)

[14.4.2 Next-Generation CAR-T 158](#_Toc72064893)

[14.5 Autolus Therapeutics, plc 159](#_Toc72064894)

[14.6 Bellicum Pharmaceuticals, Inc. 160](#_Toc72064895)

[14.6.1 GoCAR Technology 160](#_Toc72064896)

[14.6.2 Bellicum’s Pipeline 160](#_Toc72064897)

[14.7 BioNTech 161](#_Toc72064898)

[14.7.1 Collaborators 161](#_Toc72064899)

[14.7.2 Services 161](#_Toc72064900)

[14.7.3 Engineered Cell Therapies 162](#_Toc72064901)

[14.7.4 CAR-T Programs 162](#_Toc72064902)

[14.7.4.1 BNT211 162](#_Toc72064903)

[14.7.4.2 BNT212 162](#_Toc72064904)

[14.8 bluebird bio 163](#_Toc72064905)

[14.8.1 CAR-T Collaborations 163](#_Toc72064906)

[14.8.1.1 Collaboration with Celgene 163](#_Toc72064907)

[14.8.1.2 Collaboration with Inhibrx 163](#_Toc72064908)

[14.8.1.3 Collaboration with TC BioPharm 164](#_Toc72064909)

[14.9 Carina Biotech 164](#_Toc72064910)

[14.9.1 New CAR-T Cells 164](#_Toc72064911)

[14.9.2 CAR-T Access Technologies 165](#_Toc72064912)

[14.9.2.1 Chemokine Receptor Mediation 165](#_Toc72064913)

[14.9.2.2 Gel Formulation to Deliver CAR-T Cells 165](#_Toc72064914)

[14.10 CARsgen Therapeutics 166](#_Toc72064915)

[14.11 Cartesian Therapeutics, Inc. 167](#_Toc72064916)

[14.11.1 Cartesian’s Approach 167](#_Toc72064917)

[14.12 CARTherics 168](#_Toc72064918)

[14.12.1 Technology 168](#_Toc72064919)

[14.13 Celgene Corporation 169](#_Toc72064920)

[14.13.1 Lisocabtagene maraleucel (liso-cel) 169](#_Toc72064921)

[14.14 Cellectis 170](#_Toc72064922)

[14.14.1 Universal Chimeric Antigen Receptor T-Cells (UCARTs) 170](#_Toc72064923)

[14.14.1.1 UCART 123 170](#_Toc72064924)

[14.14.1.2 UCART22 171](#_Toc72064925)

[14.14.1.3 UCARTCS1 171](#_Toc72064926)

[14.14.1.4 UCART19 171](#_Toc72064927)

[14.14.1.5 ALLO-501 171](#_Toc72064928)

[14.14.1.6 ALLO-715 171](#_Toc72064929)

[14.15 Celularity, Inc. 172](#_Toc72064930)

[14.15.1 P CAR-T 172](#_Toc72064931)

[14.16 Celyad Oncology 173](#_Toc72064932)

[14.16.1 TIM Technology 173](#_Toc72064933)

[14.16.2 shRNA Technology 173](#_Toc72064934)

[14.17 Creative Biolabs 175](#_Toc72064935)

[14.17.1 CAR Construction and Production Platform 175](#_Toc72064936)

[14.18 CRISPR Therapeutics 177](#_Toc72064937)

[14.18.1 CRISPR/Cas9 Immuno-Oncology Cell Therapy 177](#_Toc72064938)

[14.19 Cytovia Therapeutics 178](#_Toc72064939)

[14.20 DiaCarta, Inc. 179](#_Toc72064940)

[14.20.1 Personalized CAR-T Immunotherapy Platform 179](#_Toc72064941)

[14.21 Empirica Therapeutics 180](#_Toc72064942)

[14.21.1 Technology 180](#_Toc72064943)

[14.22 Eureka Therapeutics, Inc. 181](#_Toc72064944)

[14.23 EXUMA Biotech Corp. 182](#_Toc72064945)

[14.23.1 Logic Gate CAR-T Technology 182](#_Toc72064946)

[14.23.2 Same-Day CAR-T Therapy 182](#_Toc72064947)

[14.24 Fate Therapeutics, Inc. 183](#_Toc72064948)

[14.25 Formula Pharmaceuticals, Inc. 184](#_Toc72064949)

[14.25.1 Technology 184](#_Toc72064950)

[14.26 Gilead Sciences, Inc. 185](#_Toc72064951)

[14.26.1 TECARTUS (Brexucabtagene autoleucel) 185](#_Toc72064952)

[14.26.2 Yescarta (Axicabtagene ciloleucel) 185](#_Toc72064953)

[14.26.3 Cell Therapy 185](#_Toc72064954)

[14.27 Gracell Biotechnologies 186](#_Toc72064955)

[14.27.1 Dual CAR 186](#_Toc72064956)

[14.27.2 FasTCAR 187](#_Toc72064957)

[14.27.3 TrUCAR 187](#_Toc72064958)

[14.28 iCell Gene Therapeutics 188](#_Toc72064959)

[14.28.1 iCell Platforms 188](#_Toc72064960)

[14.28.1.1 CARvac 188](#_Toc72064961)

[14.28.1.2 Non Gene Edited Universal CARs 188](#_Toc72064962)

[14.28.1.3 C-TPS1 189](#_Toc72064963)

[14.28.1.4 T-Cell Targeted CARs 189](#_Toc72064964)

[14.28.1.5 Compound CARs 189](#_Toc72064965)

[14.29 Janssen Biotech, Inc. 190](#_Toc72064966)

[14.29.1 JNJ-4528 190](#_Toc72064967)

[14.30 Juno Therapeutics 191](#_Toc72064968)

[14.31 JW Therapeutics, Co., Ltd. 192](#_Toc72064969)

[14.31.1 Relmacabtagene autoleucel (Relma-cel) 192](#_Toc72064970)

[14.32 Kite Pharma, Inc. 193](#_Toc72064971)

[14.32.1 Kite’s Technologies (CAR-T & TCR) 193](#_Toc72064972)

[14.32.2 Kite’s Therapies 193](#_Toc72064973)

[14.32.2.1 Yescarta (Axicabtagene ciloleucel) 193](#_Toc72064974)

[14.32.2.2 Tecartus (Brexucabtagene autoleucel) 194](#_Toc72064975)

[14.33 MaxCyte, Inc. 195](#_Toc72064976)

[14.33.1 CARMA Cell Therapies 195](#_Toc72064977)

[14.33.2 Flow Electroporation Technology 195](#_Toc72064978)

[14.34 Minerva Biotechnologies Corporation 196](#_Toc72064979)

[14.34.1 HuMNC2-CAR44 196](#_Toc72064980)

[4.35 Mustang Bio, Inc. 197](#_Toc72064981)

[14.36 Nanjing Legend Biotechnology Co., Ltd. 198](#_Toc72064982)

[14.36.1 LCAR-B38M/JNJ-4528 198](#_Toc72064983)

[14.37 Noile-Immune Biotech 199](#_Toc72064984)

[14.38 Novartis International, AG 200](#_Toc72064985)

[14.38.1 Kymriah (Tisagenlecleucel) 200](#_Toc72064986)

[14.39 Oxford Biomedica plc 201](#_Toc72064987)

[14.40 PeproMene Bio, Inc. 202](#_Toc72064988)

[14.40.1 BAFF-R CAR-T Cells 202](#_Toc72064989)

[14.41 Poseida Therapeutics, Inc. 203](#_Toc72064990)

[14.41.1 PiggyBac DNA Modification System 203](#_Toc72064991)

[14.41.2 Autologous & Allogeneic Programs 203](#_Toc72064992)

[14.41.2.1 P-BCMA-101 204](#_Toc72064993)

[14.41.2.2 P-PSMA-101 204](#_Toc72064994)

[14.41.2.3 P-BCMA-ALLO1 204](#_Toc72064995)

[14.41.2.4 P-MUC1C-ALLO1 205](#_Toc72064996)

[14.41.2.5 P-PSMA-ALLO1 205](#_Toc72064997)

[14.42 Precigen, Inc. 206](#_Toc72064998)

[14.43 Precision Biosciences 207](#_Toc72064999)

[14.44 Prescient Therapeutics 208](#_Toc72065000)

[14.44.1 OmniCAR Technology 208](#_Toc72065001)

[14.45 ProMab Biotechnologies, Inc. 209](#_Toc72065002)

[14.45.1 Custom CAR-T Cell Development 209](#_Toc72065003)

[14.46 Protheragen 210](#_Toc72065004)

[14.46.1 PR-18-01 210](#_Toc72065005)

[14.47 Sorrento Therapeutics, Inc. 211](#_Toc72065006)

[14.48 TC Biopharm 212](#_Toc72065007)

[14.48.1 Co-Stim CAR-T 212](#_Toc72065008)

[14.49 T-CURX 213](#_Toc72065009)

[14.49.1 CARAMBA 213](#_Toc72065010)

[14.50 Tessa Therapeutics, Pvt. Ltd. 214](#_Toc72065011)

[14.50.1 CD30 CAR-T Cells 214](#_Toc72065012)

[14.50.2 Allogeneic CD30-CAR EBVSTs 214](#_Toc72065013)

[14.51 Tmunity Therapeutics, Inc. 215](#_Toc72065014)

[14.52 Wugen 216](#_Toc72065015)

[14.53 Xyphos Biosciences, Inc. 217](#_Toc72065016)

[14.53.1 Xyphos’ Strategy 217](#_Toc72065017)

[14.54 Ziopharm Oncology, Inc. 218](#_Toc72065018)

[14.54.1 Non-Viral CAR-T Therapy 218](#_Toc72065019)

**APPENDIX**

[Appendix 1: Medical Centers offering CAR-T Therapies in the U.S. 219](#_Toc53242925)

**INDEX OF FIGURES**

[FIGURE 2.1: The Basic Structure of a T Cell 18](#_Toc53238670)

[FIGURE 2.2: The Binding of T Cells onto an Infected Cell 19](#_Toc53238671)

[FIGURE 2.3: Components of a CAR-T Cell 20](#_Toc53238672)

[FIGURE 2.4: The Three Domains of a CAR 21](#_Toc53238673)

[FIGURE 2.5: First Generation CARs 21](#_Toc53238674)

[FIGURE 2.6: Second Generation CARs 22](#_Toc53238675)

[FIGURE 2.7: Third Generation CARs 22](#_Toc53238676)

[FIGURE 2.8: Fourth Generation CARs 23](#_Toc53238677)

[FIGURE 2.9: Flow Chart Showing the Process of Manufacture of CAR-T Cells 25](#_Toc53238678)

[FIGURE 2.10: Diagrammatic Illustration of Autologous CAR-T 31](#_Toc53238679)

[FIGURE 2.11: Diagrammatic Illustration of Allogeneic CAR-T 32](#_Toc53238680)

[FIGURE 4.1: Leukopheresis and T Cell Isolation 39](#_Toc53238681)

[FIGURE 4.2: T Cell Culture and Transduction 40](#_Toc53238682)

[FIGURE 4.3: The Workflow in an Automated Manufacturing Unit 41](#_Toc53238683)

[FIGURE 4.4: Operating Expenses in Autologous CAR-T Manufacturing 42](#_Toc53238684)

[FIGURE 4.5: Operating Expenses in Allogeneic CAR-T Manufacturing 43](#_Toc53238685)

[FIGURE 5.1: The CAR-T Target Distribution in Global Clinical Trials 44](#_Toc53238686)

[FIGURE 6.1: CAR-T-Related Patent Publications 49](#_Toc53238687)

[FIGURE 6.2: Granted CAR-T-Related Patents 50](#_Toc53238688)

[FIGURE 6.3: Geographical Origin of CAR-T Patent Applications 51](#_Toc53238689)

[FIGURE 6.4: Top Ten CAR-T Patent Jurisdictions 52](#_Toc53238690)

[FIGURE 6.5: Affiliations of CAR-T Cell Patent Applicants 53](#_Toc53238691)

[FIGURE 7.1: Number of CAR-T Clinical Trials per Year, U.S. vs. China 59](#_Toc53238692)

[FIGURE 7.2: CAR-T Targeted Biomarkers in other Countries 63](#_Toc53238693)

[FIGURE 7.3: Percent Share of Indications Addressed by the Ongoing CAR-T Clinical Trials 66](#_Toc53238694)

[FIGURE 7.4: CAR-T Clinical Trials Phase Summary, U.S. vs. China 67](#_Toc53238695)

[FIGURE 7.5: Geographic Distribution of CAR-T Clinical Trials 81](#_Toc53238696)

[FIGURE 7.6: Distribution of CAR-T Clinical Trials by Type of CAR Generations 82](#_Toc53238697)

[FIGURE 7.7: Distribution of CAR-T Clinical Trials by Type of ScFv Used 83](#_Toc53238698)

[FIGURE 7.8: Distribution of CAR-T Clinical Trials by Type of Vectors Used 84](#_Toc53238699)

[FIGURE 8.1: Number of CAR-T-Related Published Papers in PubMed.gov 85](#_Toc53238700)

[FIGURE 10.1: Sales Revenues for Kymriah 110](#_Toc53238701)

[FIGURE 10.2: Sales Revenues for Yescarta 112](#_Toc53238702)

[FIGURE 10.3: Sales Data for Kymriah and Yescarta 113](#_Toc53238703)

[FIGURE 12.1: Global Incidence of Blood Cancers 126](#_Toc53238704)

[FIGURE 12.2: Rate of Incidence and Death for Hodgkin Lymphoma in the U.S. 127](#_Toc53238705)

[FIGURE 12.3: Rate of New NHL Cases in the U.S. 128](#_Toc53238706)

[FIGURE 12.4: Rate of New DLBCL Cases in the U.S. 129](#_Toc53238707)

[FIGURE 12.5: Rate of New FL Cases in the U.S. 130](#_Toc53238708)

[FIGURE 12.6: Rate of New Leukemia Cases in the U.S. 131](#_Toc53238709)

[FIGURE 12.7: Distribution of New Leukemia Cases in the U.S. by Type 132](#_Toc53238710)

[FIGURE 12.8: Rate of New AML Cases in the U.S. 133](#_Toc53238711)

[FIGURE 12.9: Rate of New ALL Cases in the U.S. 134](#_Toc53238712)

[FIGURE 12.10: Rate of New CML Cases in the U.S. 135](#_Toc53238713)

[FIGURE 12.11: Rate of New CLL Cases in the U.S. 136](#_Toc53238714)

[FIGURE 12.12: Rate of New MM Cases in the U.S. 137](#_Toc53238715)

[FIGURE 13.1: Estimated Global Market for CAR-T Therapy by Products, 2020-2028 148](#_Toc53238716)

[FIGURE 13.2: Global Market for CAR-T Therapy by Geography, 2020-2028 150](#_Toc53238717)

[FIGURE 13.3: Global Market for CAR-T Therapy by Indication, 2020-2028 151](#_Toc53238718)

[FIGURE 14.1: Illustration of a Dual CAR 187](#_Toc53238719)

**INDEX OF TABLES**

[TABLE 2.1: Potential CAR-Targeted Antigens Present on Hematological Malignancies 24](#_Toc53238808)

[TABLE 2.2: The Three CAR-T Therapies Crossing the Finishing Line: An Overview 26](#_Toc53238809)

[TABLE 2.2: (CONTINUED) 27](#_Toc53238810)

[TABLE 2.3: Toxicities Associated with CAR-T Treatment 28](#_Toc53238811)

[TABLE 2.4: Strategies to Improve the Safety and Efficacy of CAR-T Therapy 29](#_Toc53238812)

[TABLE 2.5: New Target Antigens and New Target Cancers 30](#_Toc53238813)

[TABLE: 2.6: A Partial List of Allogeneic CAR-T Companies 33](#_Toc53238814)

[TABLE 3.1: History of Development of CAR-T Cells 35](#_Toc53238815)

[TABLE 3.2: Approved CAR-T Products and Indications 36](#_Toc53238816)

[TABLE 3.3: The Next-Wave of CAR-T Approvals 37](#_Toc53238817)

[TABLE 3.4: Increased CAR-T Activity 37](#_Toc53238818)

[TABLE 3.5: Very Small Patient Population Addressed by CAR-T Clinical Trials 38](#_Toc53238819)

[TABLE 5.1: CAR-T Cell Target Antigens for Hematological Malignancies 45](#_Toc53238820)

[TABLE 5.2: CAR-T Target Antigens on Solid Tumors 46](#_Toc53238821)

[TABLE 6.1: Top 20 Companies in CAR-T Patent Landscape 54](#_Toc53238822)

[TABLE 6.2: TOP 20 Research Centers in CAR-T Patent Landscape 55](#_Toc53238823)

[TABLE 6.3: Top 20 CAR-T Inventors 56](#_Toc53238824)

[TABLE 6.4: Top Five CAR-T Patents with Maximum Patent Families 57](#_Toc53238825)

[TABLE 6.5: Top Five CAR-T Patents with Most Inventors in Co-Authorship 57](#_Toc53238826)

[TABLE 6.6: Top Five Patents with Most Co-Applicants 58](#_Toc53238827)

[TABLE 6.7: Top Five Patents with Most Co-Applicants 58](#_Toc53238828)

[TABLE 7.1: Percent Target Distribution of World’s CAR-T Clinical Trials 60](#_Toc53238829)

[TABLE 7.2: Targeted Biomarkers in the U.S. CAR-T Clinical Trials 61](#_Toc53238830)

[TABLE 7.3: Targeted Biomarkers in Chinese CAR-T Clinical Trials 62](#_Toc53238831)

[TABLE 7.4: Indications Addressed by CAR-T Clinical Trials in the U.S. 64](#_Toc53238832)

[TABLE 7.5: Indications Addressed by CAR-T Clinical Trials in China 65](#_Toc53238833)

[TABLE 7.6: CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S. 68](#_Toc53238834)

[TABLE 7.6: (CONTINUED) 69](#_Toc53238835)

[TABLE 7.7: CAR-T Clinical Trial Sponsor Companies and Institutions in China 70](#_Toc53238836)

[TABLE 7.7: (CONTINUED) 71](#_Toc53238837)

[TABLE 7.7: (CONTINUED) 72](#_Toc53238838)

[TABLE 7.8: CAR-T Clinical Trial Sponsor Companies and Institutions in Other Countries 73](#_Toc53238839)

[TABLE 7.9: Clinical Trials of Fourth Generation/Next-Generation and Gene-Edited CAR-T 76](#_Toc53238840)

[TABLE 7.9: (CONTINUED) 77](#_Toc53238841)

[TABLE 7.9: (CONTINUED) 78](#_Toc53238842)

[TABLE 7.9: (CONTINUED) 79](#_Toc53238843)

[TABLE 7.9: (CONTINUED) 80](#_Toc53238844)

[TABLE 8.1: A Partial List of NIH Funding for CAR-T Cell Research 86](#_Toc53238845)

[TABLE 8.1: (CONTINUED) 87](#_Toc53238846)

[TABLE 9.1: Deal-Making in CAR-T Cell Therapy Sector 91](#_Toc53238847)

[TABLE 9.1: (CONTINUED) 92](#_Toc53238848)

[TABLE 9.1: (CONTINUED) 93](#_Toc53238849)

[TABLE 9.1: (CONTINUED) 94](#_Toc53238850)

[TABLE 9.1: (CONTINUED) 95](#_Toc53238851)

[TABLE 9.1: (CONTINUED) 96](#_Toc53238852)

[TABLE 9.1: (CONTINUED) 97](#_Toc53238853)

[TABLE 9.1: (CONTINUED) 98](#_Toc53238854)

[TABLE 9.1: (CONTINUED) 99](#_Toc53238855)

[TABLE 9.1: (CONTINUED) 100](#_Toc53238856)

[TABLE 9.1: (CONTINUED) 101](#_Toc53238857)

[TABLE 9.1: (CONTINUED) 102](#_Toc53238858)

[TABLE 9.1: (CONTINUED) 103](#_Toc53238859)

[TABLE 9.1: (CONTINUED) 104](#_Toc53238860)

[TABLE 9.1: (CONTINUED) 105](#_Toc53238861)

[TABLE 9.1: (CONTINUED) 106](#_Toc53238862)

[TABLE 10.1: Sales Data for Kymriah and Yescarta 113](#_Toc53238863)

[TABLE 10.2: Efficacy, Safety and Composition of Approved CAR-T Products 117](#_Toc53238864)

[TABLE 10.3: Other Promising CAR-T Product Candidates 118](#_Toc53238865)

[TABLE 11.1: 2020 CAR-T Payment Disparities per Case in the U.S. 122](#_Toc53238866)

[TABLE 11.2: Reimbursement of CAR-T Cell Therapies in France 123](#_Toc53238867)

[TABLE 11.3: Reimbursement of CAR-T Cell Therapies in Germany 124](#_Toc53238868)

[TABLE 11.4: Reimbursement of CAR-T Cell Therapies in Italy 124](#_Toc53238869)

[TABLE 11.5: Reimbursement of CAR-T Cell Therapies in Spain 125](#_Toc53238870)

[TABLE 11.6: Reimbursement of CAR-T Cell Therapies in U.K. 125](#_Toc53238871)

[TABLE 12.1: Cost of Treating Blood Cancers 144](#_Toc53238872)

[TABLE 13.1: Estimated Global Market for CAR-T Therapy by Products, 2020-2028 147](#_Toc53238873)

[TABLE 13.2: Global Market for CAR-T Therapy by Geography, 2020-2028 149](#_Toc53238874)

[TABLE 13.3: Global Market for CAR-T Therapy by Indication, 2020-2028 151](#_Toc53238875)

[TABLE 13.4: Top Five CAR-T Companies by Marketed Products and Product Candidates 152](#_Toc53238876)

[TABLE 14.1: Atela’s Pipeline of Product Candidates 156](#_Toc53238877)

[TABLE 14.2: Allogene’s Product Pipeline 157](#_Toc53238878)

[TABLE 14.3: Anixa’s Product Pipeline 157](#_Toc53238879)

[TABLE 14.4: Autolus’ Pipeline of Clinical and Next Generation Programs 159](#_Toc53238880)

[TABLE 14.5: Bellicum Pharmaceutical’s Product Candidates 161](#_Toc53238881)

[TABLE 14.6: CARsgen’s Product Pipeline 166](#_Toc53238882)

[TABLE 14.7: Cartesian’s Product Pipeline 167](#_Toc53238883)

[TABLE 14.8: Celyad’s Product Pipeline 174](#_Toc53238884)

[TABLE 14.9: Creative Biolab’s CAR Construction and Production Platform 175](#_Toc53238885)

[TABLE 14.9: (CONTINUED) 176](#_Toc53238886)

[TABLE 14.10: CRISPR Therapeutics’ Immuno-Oncology Programs 177](#_Toc53238887)

[TABLE 14.11: Cartesian’s Product Pipeline 178](#_Toc53238888)

[TABLE 14.12: Eureka’s CAR Products in Development for Juno Therapeutics 181](#_Toc53238889)

[TABLE 14.13: iPSC-Derived Product Candidates from Fate Therapeutics 183](#_Toc53238890)

[TABLE 14.14: Formula’s Product Candidates 184](#_Toc53238891)

[TABLE 14.15: Gilead’s Cell Therapy Programs in Oncology 186](#_Toc53238892)

[TABLE 14.16: iCell’s Product Candidates 189](#_Toc53238893)

[TABLE 14.17: Juno’s CAR-T Product Candidates 191](#_Toc53238894)

[TABLE 14.18: Kite’s Pipeline of Product Candidates 194](#_Toc53238895)

[TABLE 14.19: Mustang Bio’s Product Candidates 197](#_Toc53238896)

[TABLE 14.20: Nanjing’s Autologous Product Pipeline for Hematologic Malignancies 198](#_Toc53238897)

[TABLE 14.21: Nanjing’s Allogeneic Product Pipeline for Hematologic and Solid Cancers 199](#_Toc53238898)

[TABLE 14.22: Noil’s Product Candidates for Solid Cancers 199](#_Toc53238899)

[TABLE 14.23: Oxford Biomedica’s IP Enabled and Royalty Bearing Product Candidates 201](#_Toc53238900)

[TABLE 14.24: Poseida’s Product Pipeline 204](#_Toc53238901)

[TABLE 14.25: Precigen’s CAR-T Programs 206](#_Toc53238902)

[TABLE 14.26: Precision Bioscience’s Off-the-Shelf Immunotherapy Pipeline 207](#_Toc53238903)

[TABLE 14.27: Sorrento’s Immunotherapy Pipeline 211](#_Toc53238904)

[TABLE 14.28: TC Biopharm’s Product Candidates 212](#_Toc53238905)

[TABLE 14.29: Tmunity’s CAR-T Programs for Liquid and Solid Tumors 215](#_Toc53238906)

[TABLE 14.30: Wugen’s Pipeline of Product Candidates 216](#_Toc53238907)

[TABLE 14.31: Xyphos’ Product Pipeline 217](#_Toc53238908)

[TABLE 14.32: Ziopharm’s CAR-T Product Candidates 218](#_Toc53238909)

About BioInformant:

BioInformant is the first and only market research firm to specialize in the Regenerative Medicine (RM) Industry.

BioInformant research has been cited by prominent news outlets that include Nature Biotechnology, the Wall Street Journal, CBS News, Yahoo Finance, Medical Ethics, AABB, Xconomy, and Vogue Magazine.

BioInformant serves Fortune 500 companies that include Pfizer, Goldman Sachs, and Beckton Dickinson, as well as industry start-ups and market leaders worldwide.

For more about our company and clients, visit [www.BioInformant.com](http://www.BioInformant.com).

**BioInformant Worldwide, LLC**

**www.BioInformant.com**